BeautyHealth reported first quarter 2025 results with net sales of $69.6 million, a decrease of 14.5% year-over-year, primarily due to lower delivery system sales. Despite the revenue decline, the company improved its gross margin and adjusted EBITDA, driven by cost efficiencies and a favorable shift towards consumables revenue.
Net sales for Q1 2025 were $69.6 million, a decrease of 14.5% compared to Q1 2024.
Gross margin improved to 69.8% in Q1 2025, up from 59.4% in Q1 2024.
Adjusted EBITDA was $7.3 million in Q1 2025, a significant increase from $0.4 million in Q1 2024.
Consumables net sales remained resilient, growing to $49.4 million in Q1 2025.
For the second quarter of 2025, the company expects net sales between $71 million and $76 million and adjusted EBITDA between $2 million and $4 million. For the full fiscal year 2025, net sales are projected to be between $270 million and $300 million, with adjusted EBITDA between $15 million and $25 million.
Visualization of income flow from segment revenue to net income